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BACKGROUND/PURPOSE: Oral immunization with Lactococcus lactis PppA (LPA +), a recombinant 
strain that is able to express the pneumococcal protective protein A, can improve the resistance to respira-
tory challenge with Streptococcus pneumoniae in adult mice. In this study, we investigated whether oral immu-
nization protocols using LPA+ are able to protect young mice against pneumococcal respiratory infection.
METHODS: Young mice (aged, 3 weeks) were immunized orally with LPA+ for 5 consecutive days. 
Vaccination was performed once (non-boosted group), or twice with a 2-week interval between each immu-
nization (boosted group). At the end of treatment, the specific immune responses and the resistance to 
pneumococcal infection were studied.
RESULTS: We found that the oral immunization with LPA+ was able to induce the production of specific 
antibodies in the respiratory and intestinal tracts as well as systemically. Analysis of IgG subtypes showed that 
LPA+ immunization stimulated a mixed Th1 and Th2 response. To assess whether the production of mucosal 
and systemic antibodies was able to afford protection against respiratory pneumococcal infection, challenge 
experiments with the pathogenic serotypes 3, 6B, 14, and 23F were carried out. Vaccination with LPA+ was 
able to increase resistance to infection with the four serotypes of S. pneumoniae, although the protective 
capacity of the experimental vaccine was different for each of them. Immunization decreased colonization in 
the lung, prevented bacteremia of serotypes 6B, 14, and 23F, and decreased colony counts of serotype 3.
CONCLUSION: We have shown that the oral immunization of young mice with LPA+ effectively induces 
the production of specific antibodies against the antigen PppA, both in mucosae and at the systemic level. 
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Introduction
Streptococcus pneumoniae is a major cause of morbidity and 
mortality worldwide. It asymptomatically colonizes the 
upper respiratory tract in approximately 50% of young 
children under the age of 2 years.1,2 In addition, this path-
ogen is a leading cause of bacterial meningitis, sepsis, 
pneumonia, and otitis media in young children.3,4 This 
problem is exacerbated by the increasing emergence of 
multiple-antibiotic-resistant strains, an important world-
wide issue since infants are colonized very early by resis-
tant strains, especially in developing countries.2 This fact 
has stimulated renewed interest in the prevention of 
pneumococcal infections using vaccines. Three avenues 
of pneumococcal vaccination have been explored: (1) 
polysaccharide vaccines; (2) protein-polysaccharide con-
jugate vaccines; and (3) recently, new vaccine strategies 
focused on the use of pneumococcal surface-associated 
proteins. This third strategy is the most desirable because 
immunizations with these antigens would elicit protec-
tion in high risk groups like children; and this vaccine 
would be serotype independent and cheap to produce.1 
However, mucosal immunization has been limited because 
of inefficient antigen uptake, tolerance induction, and 
proteolytic degradation of antigens before they reach the 
immune cells. Thus great efforts have been made in recent 
years to combine mucosal delivery with agents that have 
intrinsic adjuvant activity. In this sense, lactic acid bacte-
ria represent an interesting alternative for the develop-
ment of mucosal vaccines, especially because they possess 
well documented immuno-enhancing properties.5–9
The lactic acid bacterium model, Lactococcus lactis 
NZ9000, has been extensively engineered for the produc-
tion of heterologous proteins using the nisin-controlled 
gene expression system.10 We demonstrated that this 
strain, administered by the oral route, is able to improve 
the innate and specific immune responses in the respira-
tory tract.11 In addition, we used the nisin-controlled gene 
expression system, as well as the signals of the lactococcal 
Usp45 secretion peptide and of the cell wall anchoring 
protein M6 from Streptococcus pyogenes, to develop a recom-
binant strain of L. lactis able to express the pneumococcal 
protective protein A (PppA) on its surface after induction 
with nisin.12 We showed that oral immunization with the 
recombinant L. lactis PppA strain was able to induce the 
production of both systemic and mucosal (intestinal and 
respiratory) antibodies in adult immunocompetent mice.13 
Moreover, oral vaccination with L. lactis PppA strain 
improved the resistance of adult mice to respiratory chal-
lenge with different pneumococcal serotypes.13
Infectious disease is a major cause of human infant 
mortality. There are over 2.2 million annual deaths in 
children between the ages of 1 and 6 months. The infec-
tious agents responsible for these deaths may produce 
acute respiratory infections (e.g. respiratory syncytial 
virus, Bordetella pertussis, Haemophilus influenzae B, S. pneu-
moniae) or diarrheal disease (e.g. rotaviruses, Salmonella 
spp., Shigella spp.).14,15 Consequently, one of the major 
challenges in vaccinology is the development of products 
that are able to induce protective immunity in the early 
life period. Most experimental vaccines designed to pre-
vent pneumococcal infections have been studied in infec-
tion models with adult immunocompetent mice with a 
view to their future application to high risk populations 
(children, the elderly and immunocompromised individu-
als). Thus the objective of this work was to find out if the 
oral immunization protocols with L. lactis PppA that are 
effective in inducing protective immunity in adult mice 
are able to protect young mice against pneumococcal 
respiratory infection.
Methods
Immunization procedures
Male Swiss albino mice (aged, 3 weeks) were obtained 
from the closed colony at Centro de Referencia para 
The antibodies produced may play an important role in the protection against pneumococcal disease, 
since the young mice immunized with the experimental vaccine showed an increased resistance to infec-
tion with different serotypes of the pathogen.
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Lactobacilos. Animals were housed in plastic cages and 
environmental conditions were kept constant, in agree-
ment with the standards for animal housing. Each param-
eter studied was carried out in 5–6 mice for each time 
point. The Ethical Committee for Animal Care at Centro 
de Referencia para Lactobacilos approved all experimen-
tal procedures.
Recombinant L. lactis PppA was grown in M17-glu plus 
erythromycin (5 μg/mL) at 30°C until cells reached an 
OD590 of 0.6, and then induced with 50 ng/mL of nisin 
for 2 hours as previously described.12 L. lactis PppA was 
harvested by centrifugation at 3,000g for 10 minutes, then 
washed three times with sterile 0.01 M PBS, pH 7.2, and 
finally resuspended in non-fat milk to be administered to 
the mice. Mice were immunized orally with recombinant 
L. lactis PppA previously induced with nisin (L. lactis 
PppA +) at a dose of 108 cells/mouse/day, for 5 consecutive 
days, which is the optimal dose with adjuvant proper-
ties.13 Each mouse received 250 μL of the vaccine suspen-
sion orally. This immunization was performed once 
(non-boosted group), or twice with a 2-week interval be-
tween each immunization (boosted group). Mice receiving 
either the recombinant strain without induction (L. lactis 
PppA−), or sterile non-fat milk, were used as controls.
Immunofluorescence test for IgA + cells in 
lung and intestine
To determine the number of IgA + cells in the lung and 
intestine, immunofluorescence staining were performed 
on histological sections. Mice were sacrificed on Day 0 
and at the end of each immunization treatment, and 
organs were aseptically removed and processed following 
Sainte-Marie’s technique.11,16 The slices were incubated 
with α-chain anti-mouse monoclonal antibody conju-
gated with fluorescein isothiocyanate (Sigma, St. Louis, 
MO, USA). Cells were counted with a fluorescent micro-
scope using at a magnification of 100×. The results were 
expressed as the number of positive fluorescent cells per 
10 fields, representing the mean of six histological slices 
for each animal (five mice per group for each time point).
Enzyme-linked immunosorbent assay for 
anti-PppA antibodies
Serum, bronchoalveolar lavage fluid (BAL), and intestinal 
lavage fluid (IF) antibodies against PppA protein were 
determined by an enzyme-linked immunosorbent assay 
method modified from Green et al17 as previously descri-
bed.12 Briefly, plates were coated with recombinant PppA 
protein (100 μL/well of a 5 μg/mL stock in sodium car-
bonate-bicarbonate buffer, pH 9.6). Non-specific binding 
were blocked with PBS containing 5% non-fat milk. 
Samples were diluted (serum 1:200; BAL 1:20; IF 1:100) 
with PBS-Tween 20 [PBS-T; 0.05% (v/v)]. Peroxidase-
conjugated goat anti-mouse IgM, IgA, IgG, IgG1 or IgG2a 
(Fc specific; Sigma) were diluted (1:500) in PBS-T. 
Antibodies were revealed with a substrate solution (o-
phenylenediamine; Sigma) in citrate-phosphate buffer, 
pH 5.0 (containing 0.05% hyderogen peroxide) and the 
reaction was stopped by addition of 1M sulfuric acid. 
Readings were measured at 493 nm (VERSAmaxTM 
Tunable microplate reader; Molecular Devices, Sunnyvale, 
CA, USA) and samples were considered negative for the 
presence of specific antibodies when OD493 < 0.1.
Antibody avidity assay
For the measurement of IgM, IgA, and IgG antibody avid-
ity, the Enzyme-linked immunosorbent assay method was 
used. After samples were incubated, plates were washed 
and incubated for 15 minutes at room temperature with 
0.5 M sodium thiocyanate (NaSCN) to induce the dissoci-
ation of the antigen-antibody complexes. Plates were 
washed, and the remaining incubations were performed 
as described above without modification. The avidity 
index for each sample was determined as follows: the anti-
body concentration in the presence of the chaotropic 
agent NaSCN was divided by the antibody concentration 
in the absence of NaSCN and multiplied by 100.18
Opsonophagocytosis assay
Opsonophagocytic activity of BAL, IF, and serum anti-
bodies were determined by measuring the killing of live 
pneumococci by peritoneal macrophages in the presence 
of antibodies and complement.13 Isolation of peritoneal 
macrophages was performed as follows: mice (aged 6 
weeks) were anesthetized and sacrificed by cervical dislo-
cation. The peritoneal cavity was flushed with 5 mL of 
RPMI 1640 medium (Sigma). The macrophage suspen-
sion was washed twice and adjusted to a concentration of 
106 cells/mL. Test samples (serum, BAL, and IF) were also 
diluted in RPMI 1640 medium. Pneumococcal solution 
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(10 μL) containing 1,000 CFU of S. pneumoniae T14, and 
20 μL of test sample were placed in each well of a 96-well 
microtiter plate. After incubating for 30 minutes at room 
temperature, 40 μL of the peritoneal macrophage suspen-
sion (4 × 105 cells/well) and 10 μL of mouse complement 
(Sigma) were added to each well. The mixture was incu-
bated for 1 hour at 37°C. A total of 5 μL of the reaction 
mixture was plated onto Todd-Hewitt agar-yeast extract 
(Oxoid, Basingstoke, United Kingdom). The plates were 
incubated in a candle jar at 37°C for 18 hours, and then the 
surviving bacterial colonies on the plates were counted. 
The opsonization titer of each sample was defined as 
the final dilution of the serum, IF, or BAL sample that 
resulted in 50% of the colonies seen with the control well 
containing all the reactants except for the serum, IF or 
BAL respectively.
Experimental infection
Cross protective immunity was evaluated in immunized 
mice after challenge with different serotypes of S. pneumo-
niae, which were kindly provided by Dr M. Regueira of the 
Laboratory of Clinical Bacteriology, National Institute of 
Infectious Diseases, Argentina. Freshly grown colonies of 
S. pneumoniae strains AV3 (serotype 3), AV6 (serotype 6B), 
AV14 (serotype 14), and AV23 (serotype 23F) were sus-
pended in Todd-Hewitt broth and incubated at 37°C 
until the log phase of growth.12,16,19 Challenge with differ-
ent pneumococcal strains was performed 14 days after the 
end of each L. lactis PppA + immunization. Mice were chal-
lenged nasally with the pathogen by dripping 25 μL of an 
inoculum containing 106 cells into each nostril. The devel-
opment of pneumococcal disease was evaluated 48 hours 
after challenge.
Bacterial cell counts in lung and blood
Lungs were excised, weighed, and homogenized in 5 mL 
of sterile peptone water. Homogenates were diluted 
appropriately, plated in duplicate on blood agar and incu-
bated for 18 hours at 37°C. S. pneumoniae colonies were 
counted and the results were expressed as log10 CFU/g of 
organ. Progression of bacterial growth to the bloodstream 
was monitored using blood samples obtained by cardiac 
puncture with a heparinized syringe. Samples were plated 
on blood agar and bacteremia was reported as either 
negative or positive hemocultures after incubation for 18 
hours at 37°C.16,19
Statistical analysis
Experiments were performed in triplicate and results were 
expressed as mean ± standard deviation. After verification 
of a normal distribution of data, 2-way analysis of vari-
ance was used. For pairwise comparisons of the means, 
Tukey’s test was used. Differences were considered signifi-
cant at p < 0.05.
Results
L. lactis PppA + vaccination induced specific antibodies 
in serum and intestinal fluid
To evaluate the ability of L. lactis PppA + to stimulate the 
immune system associated with the intestinal mucosa, 
the levels of IgA-type anti-PppA antibodies were studied 
first. The two oral immunization protocols with L. lactis 
PppA + induced the production of specific antibodies in 
intestinal fluid, although the immunization protocol 
designed with two stimulations, 14 days apart from each 
other, more efficiently induced the production of IgA-
type anti-PppA antibodies in the gut (Table 1). No antibod-
ies were found in the groups treated with the recombinant 
bacterium without boosting (L. lactis PppA−) or with non-
fat milk. Oral immunization with L. lactis PppA + also 
induced the production of specific antibodies in serum, 
while no serum antibodies were found in the control 
groups (Table 1). In agreement with observations at 
the level of the intestinal mucosa, oral immunization 
with boosting induced the production of IgG-type anti-
PppA antibodies in serum more efficiently. We also stud-
ied the IgG1 and IgG2a levels induced by immunization 
with L. lactis PppA + , to assess the type of immunological 
response induced (Th1 or Th2), taking into account that 
Th1 cells secrete Interferon (IFN)-γ, and are associated 
with class switching to IgG2a, while Th2 cells secrete 
IL-4, IL-5 and IL-10 and promote class switching to IgG1. 
We observed that the oral administration of L. lactis 
PppA + induced a mixed Th1/Th2 response in the young 
mice, since the IgG1/IgG2a ratios were 1.5 ± 0.1 and 
1.8 ± 0.3 for the boosted and non-boosted groups, res-
pectively (Table 1).
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Oral vaccination with L. lactis PppA + induced specific 
antibodies in the respiratory tract
To evaluate whether oral immunization with L. lactis 
PppA + was able to stimulate the mobilization of IgA-
producing lymphocytes from the intestine toward the res-
piratory tract, the number of IgA + cells in these mucosae 
was determined. The number of IgA + cells in the gastroin-
testinal tract increased significantly after the administra-
tion of L. lactis PppA + (Figures 1A and 1B), immunization 
with boosting being the most efficient in stimulating this 
increase. The oral administration of L. lactis PppA + also 
increased the number of IgA + cells in lung (Figures 1C 
and 1D) and, in this case, the protocol with boosting was 
also the most efficient. The oral administration of L. lactis 
PppA− also increased the number of IgA + cells in both 
intestine and lung, which confirms our previous results 
showing that the non-recombinant strain is able to stimu-
late the IgA cycle.11 Since the administration of L. lactis 
PppA + induces the mobilization of IgA + B lymphocytes 
from the intestine to the lungs, this treatment should be 
capable of increasing the levels of anti-PppA IgA in the 
respiratory tract. To verify this, we determined the levels 
of these antibodies in BAL. Bearing in mind that other 
immunoglobulins can diffuse from the serum toward the 
pulmonary alveoli, and that they have an important role 
in respiratory defenses, we also determined the levels of 
IgM and IgG anti-PppA in BAL. After oral immunization 
with L. lactis PppA + , we detected specific IgA, IgM and 
IgG antibodies in BAL (Table 2). The vaccine plus boost-
ing protocol was the most efficient in increasing the levels 
of anti-PppA antibodies in the respiratory mucosae. This 
effect was evidenced by the IgG and IgA concentrations in 
BAL, which were significantly higher in this group than in 
the animals without boosting (Table 2). The IgG1/IgG2a 
ratios in the respiratory tract also indicated the stimula-
tion of a mixed Th1/Th2 response (Table 2).
Avidity and opsonophagocytic activity of 
anti-PppA antibodies
The avidities of the BAL, IF, and serum antibodies are 
shown in Figure 2. The avidity of the IF antibodies in the 
non-boosted L. lactis PppA + group were below 40% for 
both IgM and IgG antibodies, although IgA anti-PppA 
reached values close to 60% (Figure 2A). Boosting 
in creased the avidity of the IgG and IgA antibodies in 
IF, the latter reaching an average of 80%, which was the 
highest value observed in our study. Primary immuniza-
tion with L. lactis PppA + induced the production of anti-
PppA IgM, IgG, and IgA antibodies in BAL with avidities 
lower than 50% (Figure 2C). Boosting with L. lactis 
PppA + increased the avidity of BAL IgG and IgA, but 
did not induce changes in IgM antibody avidity. Mice 
in the boosted L. lactis PppA + group also showed serum 
anti bodies with higher avidity than mice in the non-
boosted L. lactis PppA + group (Figure 2B). Study of the 
opsonophagocytic activity of the anti-PppA antibodies 
showed that mice in the non-boosted L. lactis PppA + group 
had low titers in serum and BAL (Figure 3). Boosted ani-
mals showed significantly higher titers in serum, BAL, 
and IF (Figure 3).
Table 1. Levels of specific antibodies in serum and intestinal fluid samplesa (n = 5–6)
Group  Boost
 Intestinal fluid Serum
  IgA IgM IgG IgG1/IG2
L. lactis PppA+ No 0.577 ± 0.41 0.245 ± 0.22 0.443 ± 0.33 1.5 ± 0.1
L. lactis PppA− No  < 0.1  < 0.1 < 0.1 ND
Control No  < 0.1  < 0.1 < 0.1 ND
L. lactis PppA+  Yes 0.845 ± 0.43* 0.188 ± 0.31* 0.719 ± 0.28* 1.8 ± 0.3
L. lactis PppA− Yes  < 0.1  < 0.1 < 0.1 ND
Control Yes  < 0.1  < 0.1 < 0.1 ND
aData presented as mean ± standard deviation; *significantly different from the non-boosted group at the same time point (p < 0.05). ND = not 
determined.
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Figure 1. Number of IgA + cells in (A) intestinal tissues of non-boosted group; (B) intestinal tissues in boosted group; (C) lung tissues 
in non-boosted group and; (D) lung tissues in boosted group.*Significantly different from the control group at the same time point 
(p < 0.05); **significantly different from the control and the L. lactis PppA− groups at the same time point (p < 0.05).
Safety of L. lactis PppA + immunization
To assess the safety of L. lactis PppA + immunization in infant 
mice, weight gain and the number of deaths were monitored 
daily. No deaths occurred, and weight gain was observed 
in infant mice immunized with the experimental vaccine 
compared with the unimmunized mice (data not shown).
Protective capacity of L. lactis PppA + vaccination
Considering that the immunization protocol with boost-
ing proved to be more effective in inducing systemic and 
mucosal specific anti-PppA antigen antibodies, and in 
mobilizing the IgA + cells from the inductor sites of the 
immune system in the intestinal mucosae toward the 
lungs, we decided to assess the effectiveness of this immu-
nization scheme in providing protective immunity. Since 
cross-protection is an essential characteristic of a widely 
successful pneumococcal vaccine, a variety of pneumo-
coccal strains need to be tested to prove the effectiveness 
of the vaccine construct. Thus the ability of oral immuni-
zation with L. lactis PppA + to confer cross protective 
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Figure 2. Avidity of specific antibodies in (A) intestinal fluid, (B) 
serum, and (C) bronchoalveolar fluid samples. *Significantly dif-
ferent from the non-boosted group at the same time point 
(p < 0.05).
Table 2. Levels of specific antibodies in bronchoalveolar fluid samplesa (n = 5–6)
Group Boost 
Bronchoalveolar fluid
  IgA IgM IgG IgG1/IG2
L. lactis PppA+  No 0.425 ± 0.31 0.389 ± 0.23 0.216 ± 0.21 1.6 ± 0.1
L. lactis PppA− No  < 0.1  < 0.1  < 0.1 ND
Control No  < 0.1  < 0.1  < 0.1 ND
L. lactis PppA+  Yes 0.613 ± 0.25* 0.245 ± 0.15* 0.379 ± 0.15* 1.7 ± 0.2
L. lactis PppA− Yes  < 0.1  < 0.1  < 0.1 ND
Control Yes  < 0.1  < 0.1  < 0.1 ND
aData presented as mean ± standard deviation; *significantly different from the non-boosted group at the same time point (p < 0.05). ND = not 
determined.
immunity to the young mice was evaluated with sero-
types 3, 6B, 14, and 23F. These serotypes were selected 
according to epidemiological studies that determined 
that serotype 14 is the prevailing one in our country,20 
and also taking into account that serotypes 3, 6B, 9, 14, 
18, 19, and 23F are the ones most often associated with 
invasive disease.21 Young mice were challenged intrana-
sally with virulent pneumococcal serotypes 2 weeks after 
the last vaccine dose, and the development of pneumococ-
cal disease was evaluated 48 hours after infection. In the 
control animals without treatment, all the S. pneumoniae 
serotypes used were detected in the lung cultures and 
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hemocultures 2 days after challenge (Table 3). These 
results indicate that the four serotypes of the pathogen 
were able to colonize the respiratory tract and spread to 
the blood stream. However, the bacterial counts for sero-
type 3 in the lung were higher by one order of magnitude 
compared with serotype 6B, and by two orders of magni-
tude compared with serotypes 14 and 23F. The mice 
immunized with L. lactis PppA + by the oral route showed 
bacterial counts in the lung that were significantly lower 
than their respective controls (Table 3). Oral immuniza-
tion with the recombinant oral bacteria was effective in 
limiting the dissemination of serotypes 6B, 14, and 23F, 
since the hemocultures in these groups were negative. 
However, the oral administration of L. lactis PppA+ to 
infant mice did not prevent bacteremia caused by serotype 
3, which would be related to the greater virulence of this 
strain in our experimental model. Oral treatment with 
L. lactis PppA– improved resistance to pneumococci, but its 
protective effect was significantly lower than that observed 
in the L. lactis PppA + groups (Table 3). This fact is proba-
bly related to our previous observation showing that the 
strain L. lactis NZ9000 has the capacity to activate both 
the innate and specific immune response in the respira-
tory tract when administered by the oral route at the 
proper dose.11
Discussion
Orally administered vaccines have the distinct advantage 
of being able to potentially reach the highly concentrated 
gut associated lymphoid tissue, and induce both serum 
and secretory immune responses.22 Thus, unlike systemic 
immunization; oral delivery can induce mucosal and sys-
temic immune responses. Vaccination in early life may be 
important in protecting the individual later on. For exam-
ple, it is difficult to effectively protect elderly people (one 
of the most vulnerable groups in the population) due to 
age-related changes in the immune system (immunose-
nescence). Vaccination, or exposure to a given disease, 
early in life has been shown to confer a certain level of 
immunological memory in later life.23 In this study, we 
showed that the oral immunization of young mice with 
the recombinant lactic acid bacteria, L. lactis PppA + , was 
able to induce the production of specific antibodies both 
in the intestinal tract and at the systemic level. The effi-
cient stimulation of the gut mucosal immune system by 
L. lactis PppA + was evidenced by the increase in the 
number of IgA + cells in the intestine, and by the produc-
tion of specific anti-PppA IgA antibodies in the IF. We 
also observed an efficient stimulation of the systemic 
Table 3. Lung bacterial cell counts and hemocultures after nasal challenge with different pneumococcal serotypesa (n = 5–6)
 Bacterial cell countsa
Group Serotype 3 Serotype 6B Serotype 14 Serotype 23F
 Lung Blood Lung Blood Lung Blood Lung Blood
L. lactis PppA + 4.3 ± 0.3* 3.5 ± 0.5* 3.3 ± 0.2* < 1.5* 2.3 ± 0.2* < 1.5* 2.5 ± 0.3* < 1.5*
L. lactis PppA− 6.7 ± 0.5* 4.7 ± 0.3 4.5 ± 0.3* 3.7 ± 0.5* 4.8 ± 0.3* < 1.5* 4.9 ± 0.3* < 1.5*
Control 8.4 ± 0.2 5.1 ± 0.4 7.5 ± 0.5 4.8 ± 0.3 6.3 ± 0.4 4.7 ± 0.6 6.1 ± 0.4 4.1 ± 0.3
aThe lower limits of bacterial detection were 1.5 log CFU/g of lung and blood. Samples were taken on day 2 post-infection and data presented 
as mean ± standard deviation; *significantly different from the control group (p < 0.05).
Figure 3. Opsonophagocytic activity of antibodies in bronchoal-
veolar fluid, serum and intestinal fluid samples. *Significantly 
different from the non-boosted group at the same time point 
(p < 0.05).
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immune response after vaccination with L. lactis PppA + , 
which was evidenced by the detection of specific anti-
PppA IgG antibodies in the serum. Recent in vitro studies 
showed that L. lactis NZ9000 has intrinsic adjuvant prop-
erties, since it is able to stimulate the maturation of den-
dritic cells derived from bone marrow, and to induce the 
production of cytokines with adjuvant properties such as 
IL-1β.24 Moreover, previous in vivo studies in our lab dem-
onstrated that this lactic acid bacterium is able to stimu-
late both intestinal and systemic immunity when 
administered at the appropriate dose.11 These properties 
of L. lactis NZ9000 would explain the efficacy of oral 
immunization with L. lactis PppA + in stimulating specific 
immune responses against the S. pneumoniae antigen in 
young mice.
The analysis of IgG subtypes showed that L. lactis 
PppA + immunization stimulated a mixture of Th1 and 
Th2 responses, which is consistent with our previous 
studies in adult mice in which we observed that oral 
immunization with L. lactis PppA + was able to induce the 
production of IL-4- and IFN-γ-producing spleen cells.13 
These findings were confirmed recently by other authors, 
who demonstrated that L. lactis NZ9000 is able to stimu-
late the production of both IL-12 and IL-10 by bone mar-
row derived dendritic cells in vitro.24
It has been demonstrated that oral vaccination can 
be used to induce protective immunity in distant mucosal 
sites. The protective effect in those sites mediated by 
oral vaccines is possible because of the existence of a com-
mon mucosal immune system. When the mucosal 
immune response is induced, primed T and B cells migrate 
through the lymphatic system and enter the peripheral 
blood circulation via the thoracic duct. Extravasation 
of immune cells occurs not only in the gut lamina pro-
pria, but also in other mucosal sites such as the respira-
tory tract.25 Thus this homing pathway of primed 
lymphoid cells from the inductive sites on the Peyer’s 
patches to distant mucosal sites after antigen stimulation 
could be exploited to design recombinant L. lactis-derived 
oral vaccines that could afford protection against respira-
tory pathogens.6 In this study, we demonstrated that 
the oral immunization of young mice with L. lactis 
PppA + induced the production of specific IgA and IgG 
antibodies in the respiratory tract. The relative pro portion 
of immunoglobulins in the upper respiratory tract differs 
substantially from that in the lower respiratory tract; IgA 
prevailing in the former and IgG in the latter.26 That is 
why the presence of both immunoglobulin types with spe-
cificity for antigens of S. pneumoniae is necessary to pro-
vide better protection of the airways. Anti-pneumococcal 
IgA would reduce the colonization of the respiratory tract 
because of its capacity to limit the attachment of the 
pathogen to the epithelial cells, while anti-pneumococcal 
IgG would have a protective role in the alveoli by promoting 
phagocytosis, and by preventing local dissemination of 
the pathogen and its passage to the blood stream.26
To assess whether the production of mucosal and sys-
temic antibodies induced by oral immunization with 
L. lactis PppA + was able to afford protection against respi-
ratory infection with S. pneumoniae, challenge experiments 
with the different serotypes of the pathogen were carried 
out. Bacterial counts in lung, coupled with hemocultures, 
allowed us to conclude that young mice are more suscep-
tible than adult mice to respiratory S. pneumoniae infec-
tion, since pathogen counts in blood and lung were 
significantly higher than those previously found in adult 
mice.13 Oral immunization of young mice with L. lactis 
PppA + increased their resistance to infection with the 
four serotypes of S. pneumoniae, although the protective 
capacity of the experimental vaccine was different for each 
of them. Immunization decreased colonization in lung 
and prevented bacteremia of serotypes 6B, 14, and 23F, 
and decreased serotype 3 counts.
In conclusion, we have shown that the oral immuniza-
tion of young mice with the recombinant lactic acid 
bacteria L. lactis PppA + effectively induces the production 
of specific antibodies against the PppA antigen of 
S. pneumonia, both in mucosae and at the systemic level. 
The antibodies produced play an important role in 
protection against pneumococcal disease, since young 
mice immunized with the experimental vaccine showed 
increased resistance to infection with different serotypes 
of the pathogen. The identification of effective and safe 
strategies for the induction of protective immunity in the 
early life period requires further research, but the use of 
selected efficacious vaccines could make a tremendous 
difference in terms of infant survival worldwide. The 
results of the present paper show that oral immunization 
with recombinant bacteria represents a promising alter-
native for improving immunity in young individuals.
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